Jeffrey Meisner

Jeffrey Meisner has over 10 years of experience in scientific research and development. In 2011, they began their career as a Postdoctoral Fellow at Harvard Medical School, where they utilized genetics, molecular biology, and cellular biology to define the redundant functions of a pair of peptidoglycan hydrolases. Jeffrey then moved to Emory University in 2013, where they designed a pipeline to synthesize medically relevant bacterial polysaccharides from opportunistic human pathogens. In 2017, they joined Kaleido Biosciences as a Senior Scientist, and later became Associate Director of Biology. Jeffrey provided scientific leadership to support clinical programs in ulcerative colitis, and fostered cross-functional collaboration to identify lead compounds and test therapeutic hypotheses in pre-clinical and early clinical studies. In 2022, Jeffrey moved to Locus Biosciences, Inc. as Director of Translational Medicine, where they developed short and long-range research strategies for the Translational Medicine function across therapeutic programs. In 2023, Jeffrey became Chief Scientific Officer at Resilient Biotics.

Jeffrey Meisner received their Doctor of Philosophy (PhD) in Microbiology and Molecular Genetics from Emory University in 2010. Prior to that, they obtained a Bachelor of Science (BS) in Pharmacology from the University of California, Santa Barbara.